Exicure, Inc. XCUR

Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026

Exicure, Inc. (XCUR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $1.1 million. Free cash flow was -$887,000. As of Jun 30, 2026 it held $1.7 million in cash and investments and $0 in total debt.

Revenue
$0
Net income
$-1.12M
+57.2% vs year-ago quarter
Operating cash flow
$-887,000
+61.1% vs year-ago quarter
Free cash flow
$-887,000
+65.9% vs year-ago quarter
EPS
$-0.18
+56.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.55M
+3.6% vs year-ago quarter
Net cash
$1.72M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
XCUR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Chicago, IL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1698530
Former names
Max-1 Acquisition Corp (until Sep 28, 2017)

Other Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Revenue
$0
$0
$0
$0
$0
Operating income
-$1.1M
-$1.6M
-$2.3M
-$2.4M
-$2.5M
Net income
-$1.1M
-$1.8M
-$2.9M
-$2.4M
-$2.6M
Diluted EPS
-$0.18
-$0.29
-$0.45
-$0.39
-$0.41
Operating cash flow
-$887,000
-$1.1M
-$1.1M
-$3.5M
-$2.3M
Free cash flow
-$887,000
—
-$1.4M
-$3.6M
-$2.6M
Total assets
$11.4M
$12.8M
$14.0M
$15.3M
$18.7M
Total liabilities
$10.4M
$10.7M
$10.1M
$8.3M
$9.9M
Stockholders' equity
$977,000
$2.1M
$3.9M
$6.9M
$8.9M
Cash and investments
$1.7M
$2.6M
$3.7M
$4.4M
$7.9M
Total debt
$0
$22,000
$176,000
$366,000
$476,000

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Listing notice
Sep 16, 2026 Sep 16, 2026
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Officer or director change
Jun 30, 2026 Jun 30, 2026
8-K Current report
Regulation FD disclosure
Jun 1, 2026 Jun 1, 2026
10-Q Quarterly report May 29, 2026 Mar 31, 2026
8-K Current report
Officer or director change
Apr 10, 2026 Apr 8, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.